|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A HoosierOncology Group Trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncologist2007，12，1： | 1 |
| 2 | Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium:a phase Ⅱ Hoosier Oncology Group study显示文摘 | Li J Juliar B Yiannoutsos C | 2005 | J Clin Oncol2005，23，6： | 1 |
| 3 | Serum resistin (FIZZ3) protein is increased in obese humans显示文摘 | DEGAWA-YAMAUCHI M BOVENKERK J E JULIAR B E | 2003 | J Clin Endocrinol Metab2003，88，11： | 1 |
| 4 | Serum resistin (FIZZ3) protein is increased in obese humans显示文摘 | Degawa-Yamauchi M Bovenkerk J E Juliar B E | 2003 | J Clin Endocrinol Metab2003，88，11： | 1 |
| 5 | Serum resistin (FIZZ3) protein is increased in obese humans 显示文摘 | Degawa-Yamauchi M Bovenkerk J E Juliar B E | 2003 | Clin Endocrinol Metab2003，88，： | 1 |
| 6 | Serum reaistin (FIZZ3) protein is increased in obese humans显示文摘 | DEGAWA-YAMAUCHI M BOVENKERK J E JULIAR B E | 2003 | J Clin Endoerinol Metab2003，88，11： | 1 |
| 7 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for pa- tients with relapsed or refractory mtdtiple myeloma: a Hoosier Ontology Group Trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncolo- gist2007，12，1： | 1 |
| 8 | Serum resistin (FIZZ3)protein is increased in obese humans显示文摘 | Degawa-Yamauchi M Bovenkerk J E Juliar B E | 2003 | J Clin Endocrinol Metab2003，88，11： | 1 |
| 9 | Serum resistin (FIZZ3) protein is increased in obese humans 显示文摘 | DEGAWA YAMAUCHI M BOVENKERK J E JULIAR B E | 2003 | Clin Endocrinol Metab2003，88，： | 1 |
| 10 | Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium:a phase Ⅱ Hoosier Oncology Group study显示文摘 | Li J Juliar B Yiannoutsos C | | Journal of Clinical Oncology0，，： | 1 |
| 11 | Financial impact of pallia- tive care consult ation in a public hospital显示文摘 | Bendaly EA Groves J Juliar B | 2008 | J Palliat Med2008，11，10： | 1 |
| 12 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncologist2007，12，1： | 1 |
| 13 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HE M01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncologist2007，12，1： | 1 |
| 14 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A Hoosier Oncology Group Trial,HEM01-21显示文摘 | Suvannasankha A Fausel C Juliar B E Yiannoutsos C T Fisher W B Ansari R H | | 0，，： | 1 |
| 15 | Amiodarone hepatotoxieity in the context of the metabolic syndrome and right-sided heart failure显示文摘 | Mattar W Juliar B Gradus-Pizlo I | 2009 | Gastrointestin Liver Dis2009，18，4： | 1 |
| 16 | A phase Ⅱ trial of irinotecan (Ⅰ),5-fluorouracil (F),leucovorin (L) (IFL),celecoxib and glutamine as first line therapy for advanced colorectal cancer (CRC):A hoosier oncology group study显示文摘 | Pan C Loehrer P Juliar B | 2003 | Program/Proc Am Soc Clin Oncol2003，22，： | 1 |
| 17 | Financial impact of pallia rive care consultation in a public hospital显示文摘 | Bendaly E A Groves J Juliar B | 2008 | J Palliat Med2008，11，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员